Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
34
AMRN Quote, Financials, Valuation and Earnings
Last price:
$0.45
Seasonality move
:
13.31%
Day range:
$0.44 - $0.46
52-week range:
$0.43 - $1.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.78x
P/B ratio:
0.35x
Volume:
1.3M
Avg. volume:
1.7M
1-year change:
-49.88%
Market cap:
$187.9M
Revenue:
$306.9M
EPS (TTM):
-$0.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMRN
Amarin Corp PLC
|
$44.5M | -$0.06 | -49.46% | -50% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$20.5M | -$0.18 | 4199.24% | -9.44% | $3.50 |
|
AKTX
Akari Therapeutics PLC
|
-- | -- | -- | -- | -- |
|
DBVT
DBV Technologies SA
|
$1.1M | -$1.77 | -- | -59.89% | -- |
|
GNFT
Genfit SA
|
-- | -- | -- | -- | -- |
|
TRIB
Trinity Biotech PLC
|
$16.5M | -$0.54 | 22.88% | -58.33% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMRN
Amarin Corp PLC
|
$0.46 | -- | $187.9M | -- | $0.00 | 0% | 0.78x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.58 | $3.50 | $148.1M | -- | $0.00 | 0% | 0.81x |
|
AKTX
Akari Therapeutics PLC
|
$0.98 | -- | $24.3M | -- | $0.00 | 0% | -- |
|
DBVT
DBV Technologies SA
|
$3.04 | -- | $62.4M | -- | $0.00 | 0% | -- |
|
GNFT
Genfit SA
|
$3.67 | -- | $183.2M | 32.57x | $0.00 | 0% | 2.66x |
|
TRIB
Trinity Biotech PLC
|
$0.83 | -- | $22.8M | -- | $0.00 | 0% | 0.15x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMRN
Amarin Corp PLC
|
-- | -1.163 | -- | 2.08x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 5.180 | 20.51% | 3.54x |
|
AKTX
Akari Therapeutics PLC
|
-- | 0.396 | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -0.249 | -- | -- |
|
GNFT
Genfit SA
|
-- | -0.225 | -- | -- |
|
TRIB
Trinity Biotech PLC
|
147.47% | -4.660 | 785.94% | 0.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMRN
Amarin Corp PLC
|
$16.3M | -$25.2M | -7.2% | -7.2% | -59.5% | -$2.4M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AKTX
Akari Therapeutics PLC
|
-- | -$1.9M | -- | -- | -- | -$1.5M |
|
DBVT
DBV Technologies SA
|
-- | -$30.3M | -- | -- | -- | -$22.9M |
|
GNFT
Genfit SA
|
-- | -- | -- | -- | -- | -- |
|
TRIB
Trinity Biotech PLC
|
$5.3M | -$2.2M | -45.03% | -- | -11.29% | -$6.3M |
Amarin Corp PLC vs. Competitors
-
Which has Higher Returns AMRN or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -59.42% compared to Amarin Corp PLC's net margin of -43.07%. Amarin Corp PLC's return on equity of -7.2% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp PLC38.48% -$0.06 $531.4M ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About AMRN or ADAP?
Amarin Corp PLC has a consensus price target of --, signalling upside risk potential of 118.96%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $3.50 which suggests that it could grow by 291.62%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Amarin Corp PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Amarin Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp PLC0 2 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is AMRN or ADAP More Risky?
Amarin Corp PLC has a beta of 1.831, which suggesting that the stock is 83.086% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.863%.
-
Which is a Better Dividend Stock AMRN or ADAP?
Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or ADAP?
Amarin Corp PLC quarterly revenues are $42.3M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Amarin Corp PLC's net income of -$25.1M is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.78x versus 0.81x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp PLC0.78x -- $42.3M -$25.1M ADAPAdaptimmune Therapeutics PLC0.81x -- $40.9M -$17.6M
-
Which has Higher Returns AMRN or AKTX?
Akari Therapeutics PLC has a net margin of -59.42% compared to Amarin Corp PLC's net margin of --. Amarin Corp PLC's return on equity of -7.2% beat Akari Therapeutics PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp PLC38.48% -$0.06 $531.4M AKTXAkari Therapeutics PLC-- -$0.24 -- -
What do Analysts Say About AMRN or AKTX?
Amarin Corp PLC has a consensus price target of --, signalling upside risk potential of 118.96%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 8063.27%. Given that Akari Therapeutics PLC has higher upside potential than Amarin Corp PLC, analysts believe Akari Therapeutics PLC is more attractive than Amarin Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp PLC0 2 0 AKTXAkari Therapeutics PLC0 0 0 -
Is AMRN or AKTX More Risky?
Amarin Corp PLC has a beta of 1.831, which suggesting that the stock is 83.086% more volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.791, suggesting its less volatile than the S&P 500 by 20.903%.
-
Which is a Better Dividend Stock AMRN or AKTX?
Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or AKTX?
Amarin Corp PLC quarterly revenues are $42.3M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Amarin Corp PLC's net income of -$25.1M is lower than Akari Therapeutics PLC's net income of -$2.9M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.78x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp PLC0.78x -- $42.3M -$25.1M AKTXAkari Therapeutics PLC-- -- -- -$2.9M
-
Which has Higher Returns AMRN or DBVT?
DBV Technologies SA has a net margin of -59.42% compared to Amarin Corp PLC's net margin of --. Amarin Corp PLC's return on equity of -7.2% beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp PLC38.48% -$0.06 $531.4M DBVTDBV Technologies SA-- -$1.60 -- -
What do Analysts Say About AMRN or DBVT?
Amarin Corp PLC has a consensus price target of --, signalling upside risk potential of 118.96%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 624.09%. Given that DBV Technologies SA has higher upside potential than Amarin Corp PLC, analysts believe DBV Technologies SA is more attractive than Amarin Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp PLC0 2 0 DBVTDBV Technologies SA0 0 0 -
Is AMRN or DBVT More Risky?
Amarin Corp PLC has a beta of 1.831, which suggesting that the stock is 83.086% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.
-
Which is a Better Dividend Stock AMRN or DBVT?
Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or DBVT?
Amarin Corp PLC quarterly revenues are $42.3M, which are larger than DBV Technologies SA quarterly revenues of --. Amarin Corp PLC's net income of -$25.1M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.78x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp PLC0.78x -- $42.3M -$25.1M DBVTDBV Technologies SA-- -- -- -$30.4M
-
Which has Higher Returns AMRN or GNFT?
Genfit SA has a net margin of -59.42% compared to Amarin Corp PLC's net margin of --. Amarin Corp PLC's return on equity of -7.2% beat Genfit SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp PLC38.48% -$0.06 $531.4M GNFTGenfit SA-- -- -- -
What do Analysts Say About AMRN or GNFT?
Amarin Corp PLC has a consensus price target of --, signalling upside risk potential of 118.96%. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could grow by 180.13%. Given that Genfit SA has higher upside potential than Amarin Corp PLC, analysts believe Genfit SA is more attractive than Amarin Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp PLC0 2 0 GNFTGenfit SA0 0 0 -
Is AMRN or GNFT More Risky?
Amarin Corp PLC has a beta of 1.831, which suggesting that the stock is 83.086% more volatile than S&P 500. In comparison Genfit SA has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.458%.
-
Which is a Better Dividend Stock AMRN or GNFT?
Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or GNFT?
Amarin Corp PLC quarterly revenues are $42.3M, which are larger than Genfit SA quarterly revenues of --. Amarin Corp PLC's net income of -$25.1M is higher than Genfit SA's net income of --. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.78x versus 2.66x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp PLC0.78x -- $42.3M -$25.1M GNFTGenfit SA2.66x 32.57x -- --
-
Which has Higher Returns AMRN or TRIB?
Trinity Biotech PLC has a net margin of -59.42% compared to Amarin Corp PLC's net margin of -31.41%. Amarin Corp PLC's return on equity of -7.2% beat Trinity Biotech PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AMRNAmarin Corp PLC38.48% -$0.06 $531.4M TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M -
What do Analysts Say About AMRN or TRIB?
Amarin Corp PLC has a consensus price target of --, signalling upside risk potential of 118.96%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 1712.69%. Given that Trinity Biotech PLC has higher upside potential than Amarin Corp PLC, analysts believe Trinity Biotech PLC is more attractive than Amarin Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings AMRNAmarin Corp PLC0 2 0 TRIBTrinity Biotech PLC0 0 0 -
Is AMRN or TRIB More Risky?
Amarin Corp PLC has a beta of 1.831, which suggesting that the stock is 83.086% more volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 0.969, suggesting its less volatile than the S&P 500 by 3.133%.
-
Which is a Better Dividend Stock AMRN or TRIB?
Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMRN or TRIB?
Amarin Corp PLC quarterly revenues are $42.3M, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. Amarin Corp PLC's net income of -$25.1M is lower than Trinity Biotech PLC's net income of -$4.8M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.78x versus 0.15x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMRNAmarin Corp PLC0.78x -- $42.3M -$25.1M TRIBTrinity Biotech PLC0.15x -- $15.2M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is down 5.23% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.6% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 1.59% over the past day.
